Peter Elliott

Scientific Advisor at Jupiter Orphan Therapeutics, Inc.

Peter Elliott

Peter Elliott

Scientific Advisor at Jupiter Orphan Therapeutics, Inc.

Overview
RelSci Relationships

608

Number of Boards

1

Birthday

1960

Age

61

Contact Data
Trying to get in touch with Peter Elliott? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Peter Elliott likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founding Member at Whitehead Institute for Biomedical Research

Relationship likelihood: Strong

Chief Executive Officer & Director at Verastem, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Celularity, Inc.

Relationship likelihood: Strong

Former Executive Chairman at Blackthorn Therapeutics, Inc.

Relationship likelihood: Strong

Cxo at EQRx, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Ardelyx, Inc.

Relationship likelihood: Strong

Chief Operating & Legal Officer at bluebird bio, Inc.

Relationship likelihood: Strong

President & Chief Operating Officer at Verastem, Inc.

Relationship likelihood: Strong

Executive Vice President, Chief Financial & Accounting Officer at Collegium Pharmaceutical, Inc.

Relationship likelihood: Strong

Chief Financial & Business Officer at Verastem, Inc.

Relationship likelihood: Strong

Paths to Peter Elliott
Potential Connections via
Relationship Science
You
Peter Elliott
Scientific Advisor at Jupiter Orphan Therapeutics, Inc.
Education
Ph.D. in Psychopharmacology

The University of Cambridge (informally known as Cambridge University or Cambridge) is a public research university located in Cambridge, United Kingdom. It is the second-oldest university in the English-speaking world (after the University of Oxford), and the seventh-oldest in the world.

B.S. in Pharmacology

The University of London is a collegiate research university located in London, England, consisting of 18 constituent colleges, 10 research institutes and a number of central bodies. The nine largest institutions of the federal university, usually termed the colleges, are Birkbeck, Goldsmiths, King's College London, the London Business School, Queen Mary, Royal Holloway, SOAS, LSE and UCL. Formerly a constituent college, Imperial College London left the University of London in 2007.

Career History
Head, Research & Development
2005 - Prior

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas.Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases.Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass.Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Vice President, Pharmacology & Drug Development
1998 - 2001

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Executive Vice President-Product Development
2001 - 2005

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Boards & Committees
Member, Scientific Advisory Board
Current

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Investments
Details Hidden

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas.Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases.Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass.Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Peter Elliott. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Peter Elliott's profile does not indicate a business or promotional relationship of any kind between RelSci and Peter Elliott.